An update on dengue vaccine development, challenges, and future perspectives

Idris, Fakhriedzwan; Ting, Donald Heng Rong; Alonso, Sylvie

doi:10.1080/17460441.2020.1811675

Cited by 31 publications

(26 citation statements)

References 140 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Currently, treatment remains supportive and no effective antiviral agents exist [4] . Although Dengvaxia, the only FDA-approved dengue vaccine, is licenced in 20 countries, the WHO did not recommend its use in seronegatives [6] . Thus, current dengue control relies mainly on combinations of chemical and biological targeting against larval or adult mosquitoes [7] .…”

Section: Introductionmentioning

confidence: 99%

Global, regional, and national dengue burden from 1990 to 2017: A systematic analysis based on the global burden of disease study 2017

et al. 2021

View full text Add to dashboard Cite

Background Dengue is one of the most common vector-borne diseases globally, however, its burden is poorly quantified. Hence, we aimed to report the dengue burden in 195 countries and territories between 1990 and 2017, using data from the Global Burden of Diseases, Injuries, and Risk Factors Study 2017. Methods Following the methodology framework and analytical strategies used in the Global Burden of Disease Study 2017, we analysed the incidence, mortality, and disability-adjusted life years (DALYs) of dengue in geographically defined populations worldwide between 1990 and 2017. We also determined the association between development levels and dengue burden. All estimates were reported as numbers and rates per 100 000 population, with 95% uncertainty intervals. Findings Globally, the total number of dengue cases increased from 23 283 274 (95% UI 453 180.7–51 840 670) in 1990 to 104 771 911 (95% UI 63 759 019–158 870 031) in 2017. The age-standardised incidence rate increased from 431.6 (8.4–961.0) per 100 000 population in 1990 to 1371.3 (834.5–2079.3) per 100 000 population in 2017. In addition, the number of deaths due to dengue increased from approximately16 957 (7 613–30 091) in 1990 to 40 467 (17 620–49 778) in 2017. Meanwhile, the global age-standardised death rate increased from 0.31 (0.14–0•56) per 100 000 population in 1990 to 0.53 (0.23–0•65) per 100 000 population in 2017. Overall, there were 2 922 630 DALYs (1 629 424–3 967 492) attributed to dengue in 2017 globally, an increase of 107.6% since 1990 (1 407 571 DALYs [624 016.4–2 510 025]), and the age-standardised DALY rate increased from 26.10 (11.57–46.53) per 100 000 population to 38.25 (21.33–51.93) per 100 000 population between 1990 and 2017. The association between socio-demographic index (SDI) and dengue-related DALYs suggested that the lowest age-standardised DALY rates were found in countries in the low and high-SDI quintile in 2017, and from 1990 to 2017, the age-standardized DALY rate tended to increase in regions with the lowest SDI but declined in regions with the highest SDI. There was a nonlinear association between the socio-demographic index and the healthcare access and quality index and age-standardised DALY rates. Interpretation Dengue is a major public health challenge worldwide. While there is remarkable international variation in its incidence, the dengue burden is increasing globally. The results of this study could be useful for policy makers to implement cost-effective interventions and reduce the dengue burden, particularly in countries with high incidence or increasing burden. Funding This work was supported by a grant from the National Natural Science Foundation of China (NSFC) (grant numbers 81,800,041 and 82,000,078).

show abstract

Section: Introductionmentioning

confidence: 99%

Global, regional, and national dengue burden from 1990 to 2017: A systematic analysis based on the global burden of disease study 2017

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Unfortunately, there remain many diseases where vaccines are either unavailable or ineffective, including HIV, malaria, and cancer. Dengue is currently the most serious mosquito borne infection (Diamond and Pierson 2015 ), and while some dengue vaccines have reached the clinical trial stage and even received regulatory approval, no vaccine has gained universal acceptance (Idris et al 2020 ). With the ongoing SARS-CoV-2 pandemic taking up so many public health resources, the imperative of improving the vaccine development process to prevent other infectious diseases is very clear.…”

Section: Discussionmentioning

confidence: 99%

Expression of an immunocomplex consisting of Fc fragment fused with a consensus dengue envelope domain III in Saccharomyces cerevisiae

Chun

Lương

et al. 2021

Biotechnol Lett

View full text Add to dashboard Cite

Objectives To explore Saccharomyces cerevisiae as an expression platform for dengue oral immune complex vaccine development. Results Molecular engineering was applied to create a fusion gene construct (scEDIII-PIGS) consisting of a yeast codon optimized sequence encoding for a synthetic consensus dengue envelope domain III (scEDIII) followed by a modified IgG Fc domain (PIGS). Northern blot showed transcription of the target gene, with a temporal expression pattern similar to those from previous work. Western blot showed assembly of various immune complexes from monomer to hexamer. Partial purification of scEDIII-PIGS was also attempted to demonstrate the feasibility of yeast system for immune complex vaccine development. Approximately 1 mg of scEDIII-PIGS can be produced from 1 l culture. Conclusion This work demonstrated for the first time that various immunocomplex structures of our target protein could be efficiently produced in S. cerevisiae for future application in developing oral and injectable vaccines against various pathogens.

show abstract

“…For details of the dengue vaccine candidates and their development, please refer to the study by Pinheiro-Michelsen et al (2020) . Several vaccine candidates, including TAK-003, TV003/TV005, TDENF17/F19, TDEN PIV, V180, and TVDV, are present in the clinical pipeline ( Idris et al, 2021 ). Here, we will briefly discuss the first dengue vaccine, CYD-TDV, and other dengue vaccine candidates, including TAK-003 and TV003/TV005, in their late-stage development.…”

Section: Denv Vaccines Under Developmentmentioning

confidence: 99%

“…However, it has become challenging to develop a universal DENV vaccine owing to some limitations. One of the major limitations in DENV vaccine development is the existence of multiple DENV subtypes and different virulence mechanisms in different strains ( Idris et al, 2021 ). ADE of disease appears to be a public health concern regarding the development of vaccines and antibody therapies; the mechanisms underlying antibody protection against viruses might have the potential to enhance infection or induce immunopathology ( Arvin et al, 2020 ).…”

Section: Challenges To Overcome In Denv Vaccine Developmentmentioning

confidence: 99%

Recent Insights Into the Molecular Mechanism of Toll-Like Receptor Response to Dengue Virus Infection

2021

View full text Add to dashboard Cite

Dengue is the most prevalent and rapidly spreading mosquito-borne viral disease caused by dengue virus (DENV). Recently, DENV has been affecting humans within an expanding geographic range due to the warming of the earth. Innate immune responses play a significant role in antiviral defense, and Toll-like receptors (TLRs) are key regulators of innate immunity. Therefore, a detailed understanding of TLR and DENV interactions is important for devising therapeutic and preventive strategies. Several studies have indicated the ability of DENV to modulate the TLR signaling pathway and host immune response. Vaccination is considered one of the most successful medical interventions for preventing viral infections. However, only a partially protective dengue vaccine, the first licensed dengue vaccine CYD-TDV, is available in some dengue-endemic countries to protect against DENV infection. Therefore, the development of a fully protective, durable, and safe DENV vaccine is a priority for global health. Here, we demonstrate the progress made in our understanding of the host response to DENV infection, with a particular focus on TLR response and how DENV avoids the response toward establishing infection. We also discuss dengue vaccine candidates in late-stage development and the issues that must be overcome to enable their success.

show abstract

An update on dengue vaccine development, challenges, and future perspectives

Cited by 31 publications

References 140 publications

Global, regional, and national dengue burden from 1990 to 2017: A systematic analysis based on the global burden of disease study 2017

Global, regional, and national dengue burden from 1990 to 2017: A systematic analysis based on the global burden of disease study 2017

Expression of an immunocomplex consisting of Fc fragment fused with a consensus dengue envelope domain III in Saccharomyces cerevisiae

Recent Insights Into the Molecular Mechanism of Toll-Like Receptor Response to Dengue Virus Infection

Contact Info

Product

Resources

About